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BACKGROUND & AIMS: Liver ischemia/reperfusion
(I/R) injury is a frequent cause of organ dysfunction. Loss
of the oxygen sensor prolyl hydroxylase domain enzyme
1 (PHD1) causes tolerance of skeletal muscle to hypoxia.
We assessed whether loss or short-term silencing of
PHD1 could likewise induce hypoxia tolerance in hepa-
tocytes and protect them against hepatic I/R damage.
METHODS: Hepatic ischemia was induced in mice by
clamping of the portal vessels of the left lateral liver lobe;
90 minutes later livers were reperfused for 8 hours for I/R
experiments. Hepatocyte damage following ischemia or
I/R was investigated in PHD1-deficient (PHD1!/!) and
wild-type mice or following short hairpin RNA-mediated
short-term inhibition of PHD1 in vivo. RESULTS:
PHD1!/! livers were largely protected against acute is-
chemia or I/R injury. Among mice subjected to hepatic
I/R followed by surgical resection of all nonischemic liver
lobes, more than half of wild-type mice succumbed,
whereas all PHD1!/! mice survived. Also, short-term in-
hibition of PHD1 through RNA interference!mediated
silencing provided protection against I/R. Knockdown of
PHD1 also induced hypoxia tolerance of hepatocytes in
vitro. Mechanistically, loss of PHD1 decreased produc-
tion of oxidative stress, which likely relates to a decrease
in oxygen consumption as a result of a reprogramming of
hepatocellular metabolism. CONCLUSIONS: Loss of
PHD1 provided tolerance of hepatocytes to acute
hypoxia and protected them against I/R-damage.
Short-term inhibition of PHD1 is a novel therapeutic
approach to reducing or preventing I/R-induced liver
injury.
Keywords: PHD1; Prolyl Hydroxylase; Ischemia/Reper-
fusion.
Liver dysfunction due to ischemia/reperfusion (I/R)damage is a frequent clinical complication of inter-
rupted hepatic blood flow that occurs in low-flow states
and in patients undergoing liver surgery. I/R injury is the
main cause of failure of liver allografts and an important
problem influencing outcomes of transplantations in
clinical practice.1 Liver I/R injury arises as a result of
various consecutive pathophysiologic processes.2 Ini-
tially, oxygen shortage causes metabolic pertubation with
mitochondrial dysfunction and energy deficiency in is-
chemic hepatocytes.3 The resultant hepatocyte swelling
contributes to narrowing of sinusoidal blood vessels and
accumulation of leukocytes in sinusoids.4 A substantial
inflammatory response follows, causing parenchymal in-
jury, in part through excess production of toxic reactive
oxygen species (ROS)5 and degradative enzymes.6 Thus,
mitochondrial dysfunction and energy deficiency early in
the ischemic phase trigger a chain of deleterious patho-
physiologic responses, ultimately causing hepatocyte
death and liver dysfunction.2
The prolyl hydroxylase domain (PHD) enzymes PHD1,
PHD2, and PHD3 are oxygen sensors that regulate the
stability of hypoxia inducible transcription factors (HIFs)
in an oxygen-dependent manner, thus mediating cellular
adaptive responses to changes in oxygen supply.7,8 We re-
cently demonstrated that loss of PHD1 protects ischemic
skeletal muscle against mitochondrial dysfunction and
toxic ROS formation.9 Hypoxia tolerance of PHD1!/!
skeletal muscle cells relied on metabolic reprogramming
that attenuated mitochondrial oxidative metabolism and
oxygen consumption. These changes already occurred in
baseline conditions and were mediated via HIF-2! (and
HIF-1!), as well as by enhanced expression of the meta-
bolic adaptors, pyruvate dehydrogenase kinase (PDK)
isoenzymes PDK1 and -4.9
Abbreviations used in this paper: ALT, alanine aminotransferase;
HIF, hypoxia inducible factor; I/R, ischemia/reperfusion; 8-OHdG, 8-hy-
droxy-2=-deoxyguanosine; PDC, pyruvate dehydrogenase enzyme com-
plex; PDK, pyruvate dehydrogenase kinase; PHD, prolyl hydroxylase
domain; ROS, reactive oxygen species; WT, wild-type.
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Here, we determined whether loss or silencing of
PHD1 likewise protected hepatocytes against hypoxic
damage and, if so, whether this hypoxic protection was
sufficient to attenuate hepatic I/R injury. We report that
PHD1-deficiency reduces liver cell damage and hepatic
dysfunction in a model of murine liver I/R. Notably, this
beneficial effect was also achieved by short-term silencing
of PHD1 in the liver. These findings highlight the ther-
apeutic potential of short-term inhibition of PHD1 to
prevent ischemic liver injury.
Materials and Methods
Mouse Models
Inactivation of PHD1 has been described else-
where (Supplementary Note 1).9 Male WT and PHD1!/!
mice aged 10 to 12 weeks were used for experiments. To
induce hepatic ischemia, portal vessels of the left lateral
liver lobe were clamped. Sham-operated animals under-
went median laparotomy and liver manipulation without
clamping. Animals were sacrificed after 90 minutes of
ischemia or after 90 minutes of ischemia followed by 8
hours of reperfusion (I/R). In survival experiments, the
lateral liver lobe was clamped for 90 minutes and non-
ischemic liver lobes were ligated and resected immedi-
ately after removal of the clamp. Thirty percent of WT
and 40% of PHD1!/! mice died within 2 hours of hepa-
tectomy due to surgical trauma and were excluded from
further analysis. Sinusoidal perfusion was assessed by
intravital microscopy. The lateral liver lobe was exterior-
ized on a mechanical stage, its upper surface placed
under a fluorescent microscope for epi-illumination, and
continuously superfused with prewarmed Ringer’s solu-
tion. A 1:1 solution of fluorescein isothiocyanate!labeled
erythrocytes was administered via a jugular catheter.
Mean erythrocyte velocity was analyzed offline applying a
computer-assisted software (Cap Image, Zeintl, Heidel-
berg, Germany) based on intravital imaging movies of
perfused liver acini, and sinusoidal diameter was mea-
sured perpendicularly to the vessel path. The ratio of
perfused sinusoids (representing the percentage of per-
fused sinusoids in relation to all visible sinusoids) was
around 95% in WT and PHD1!/! mice, and was not
significantly impaired when erythrocyte velocity was re-
corded immediately after ischemia. Real-time reverse
transcription polymerase chain reaction and immuno-
blotting were performed as described previously (Supple-
mentary Note 2).
Histology and Immunostaining
For histological assessment of liver cell damage,
paraffin sections were stained with hematoxylin and eo-
sin, and the area of hepatocytes with clearly definable
borders (at least 120 cells per specimen) was determined
morphometrically. For immunostaining, sections were
digested with 0.2% trypsin (Sigma, Hamburg, Germany),
blocked, and incubated overnight with primary antibod-
ies: rat anti-CD45 (BD Pharmingen, San Diego, CA;
1/100), rat anti-CD31 (BD Pharmingen; 1/100), or mouse
anti!8-hydroxy-2=-deoxyguanosine (8-OHdG) (Oxis In-
ternational, Beverly Hills, CA; dilution 1/20). Sections
were incubated with appropriate secondary antibodies
and developed with 3,3-diaminobenzidine (Sigma). For
detection of hypoxic cells, mice were treated with pi-
monidazole (Chemicon, Temecula, CA) 1 hour before
collecting the liver; and liver sections were stained with
the Hydroxyprobe1 antibody (Chemicon). Apoptosis was
evaluated by TUNEL staining (Roche Diagnostics, Mann-
heim, Germany). All microscopic quantification analyses
were performed in 12 standardized optical fields per
specimen by 2 individual investigators using Zeiss KS300
morphometry software (Zeiss, Jena, Germany).
Metabolite Concentrations and PDC Activity
Liver metabolites and levels of energy-rich sub-
strates were measured by enzymatic methods, and deter-
mination of pyruvate dehydrogenase enzyme complex
(PDC) activity was performed on pulverized and homog-
enized liver tissue as described.10 The cellular energy
charge was calculated by applying the formula ([ATP] "
0.5[ADP] / [ATP] " [ADP] " [AMP]).11 Relative ratio of
glutathione-disulfide to total glutathione was assessed
applying a glutathione colorimetric assay kit (Oxis GSH/
GSSG-412) according to manufacturer’s instructions.
Cell Culture Experiments
Hepatocytes were isolated using a 2-step collage-
nase perfusion technique as described.12 Oxygen con-
sumption was assessed in a high-resolution respirome-
ter (OROBOROS, Innsbruck, Austria) at 37°C as des-
cribed.13 To simulate I/R in vitro, hepatocytes were
incubated in Krebs-Ringer-HEPES buffer at acidic pH in
a hypoxic chamber (0.5% O2) for 4 hours.14 Subsequently,
hypoxic Krebs-Ringer-HEPES was replaced by aerobic
growth medium containing WST-1 cell proliferation re-
agent (Roche) to simulate reperfusion. The quantity of
formazan dye resulting from mitochondrial cleavage of
the tetrazolium salt WST-1, which is indicative of the
number of viable cells, was quantified after 2 hours by
measuring the absorbance at 450 nm.
Short-Term Inhibition of PHD1 in Mice
An shPHD1KD construct (5=–CACCGCTGCATC-
ACCTGTATCTATTTCTCTTGAAA ATAGATACAGGT-
GATGCAGC) was designed as described (www.invitrogen.
com/mai) to produce short hairpin interference RNA
against PHD1 in vivo.9 As control, we used an shPHD1CTR
construct (5=–CACCGCTTAACCCGTATTGCCTATTTC-
TCTTGAAAATA GGCAATACG GGTTAAGC). shPHD1CTR
and shPHD1KD were cloned in an adenoviral expression
system (pAd/BLOCK-iT-DEST; Invitrogen, Carlsbad, CA)
applying the Invitrogen Gateway Technology (AdshPHD1CTR
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and AdshPHD1KD, respectively; Supplementary Note 3).
AdshPHD1KD and AdshPHD1CTR (5 # 109 plaque-forming
units) in 100 "L saline were administered via tail vein
injection.
Statistics
All values are represented as mean $ standard
error of mean. The difference between means was ana-
lyzed with Student’s t test. P values %.05 were considered
significant. Log-rank test was applied to assess survival of
mice subjected to liver ischemia and resection.
Results
Hypoxia Tolerance in Ischemic PHD1!/!
Livers
We first determined the expression of the PHDs in
the liver. Each PHD was detectable in the liver of WT
mice; in PHD1!/! livers, PHD1 was undetectable, while
PHD2 and PHD3 were not compensatorily up-regulated
(Supplementary Note 4; Supplementary Figure S1A). Liv-
ers of PHD1!/! mice appeared normal (Figure 1A; Sup-
plementary Note 1). To assess whether loss of PHD1
protects hepatocytes against ischemic damage, portal ves-
sels were occluded for 90 or 180 minutes. Loss of PHD1
did not protect hepatocytes against 3 hours of ischemia
(Supplementary Note 5; Supplementary Figure 1B). This
finding is not surprising, given that mammalian cells
ultimately need oxygen to survive. However, PHD1!/!
hepatocytes exhibited a remarkable protection against
ischemic stress of 90 minutes. Indeed, histology of is-
chemic WT livers after 90 minutes ischemia revealed
hepatocyte swelling, vacuolization, and karyolysis, while
signs of hypoxic cell damage were markedly attenuated in
ischemic PHD1!/! livers (Figure 1B). We determined he-
patocyte size as an index of cellular injury, as it was a
reliable quantifiable parameter. Analysis revealed that
hepatocyte size in WT livers was increased in ischemic
conditions (consistent with previous observations15); in
contrast, no significant swelling of ischemic hepatocytes
was observed in PHD1!/! livers (Figure 1C).
Because hepatic sinusoidal vessels are compressed by
swelling of ischemic hepatocytes,15 we measured their
diameter. As shown in Figure 1D, lumen size of these
vessels was decreased in WT livers after 90 minutes of
ischemia, but maintained in ischemic PHD1!/! livers. We
also determined sinusoidal blood flow by intravital fluo-
rescence microscopy after releasing of 90 minutes vascu-
lar occlusion. In baseline conditions, sinusoidal erythro-
cyte velocity was comparable in both genotypes (Figure
1E). After ischemia, sinusoidal flow in postischemic lobes
was increased in both genotypes, reflecting reactive hy-
peremia.16 However, sinusoidal microcirculation was
higher in postischemic PHD1!/! livers (Figure 1E), con-
sistent with reduced damage of PHD1!/! hepatocytes.
This protection against ischemic injury was not due to a
genotypic difference in the supply of oxygen in baseline
conditions, as PHD1!/! mice had normal blood oxygen
and hemoglobin levels,9 and formed a normal liver mi-
crovasculature (Supplementary Note 6; Supplementary
Figure S2), Thus, loss of PHD1 attenuated hypoxic swell-
ing of hepatocytes and resultant compression of sinusoi-
dal vessels in ischemic livers.
The observation that PHD1!/! livers were hypoxia-
tolerant suggested that PHD1!/! hepatocytes were still
capable of producing sufficient energy to survive, even
despite the reduced oxygen supply. We therefore mea-
sured the cellular energy charge. In baseline conditions,
this parameter was comparable in WT and PHD1!/!
livers (Figure 1F). After 20 minutes of ischemia, the
energy charge steeply decreased to 40% of baseline levels
in WT hepatocytes and continued to decline progres-
sively during the 60 minutes thereafter (Figure 1F). In
PHD1!/! livers, the energy charge similarly dropped
acutely during the initial 20 minutes of ischemia but
thereafter did not decrease as rapidly and progressively as
in WT hepatocytes (Figure 1F). Liver cells are sensitive to
changes in cellular energy charge, and even small changes
below a critical threshold can have a substantial impact
on cellular function and survival.17,18 Nonetheless, while
these data indicate that PHD1!/! hepatocytes were capa-
ble of preserving vital amounts of adenosine triphosphate
in ischemic conditions, sufficient to prevent swelling, the
absence of more dramatic genotypic differences in cellular
energy charge suggested that additional mechanisms (re-
duced oxidative stress) might also contribute to protection
of PHD1!/! hepatocytes against ischemia. In particular, it is
conceivable that HIF-induced target genes, such as endo-
thelial nitric oxide synthase, may enhance postischemic mi-
crocirculation in PHD1!/! livers (Supplementary Note 7).16
Loss of PHD1 Protects Hepatocytes Against
I/R Injury
Hepatocyte swelling and narrowing of sinusoidal
vessels are key events in the induction of hepatic I/R
damage.2,3 Given that these parameters were reduced in
PHD1!/! livers, we also analyzed whether PHD1!/! livers
were more tolerant against I/R injury. Therefore, animals
were subjected to hepatic ischemia (90 minutes) and
reperfusion (8 hours) when all analyses were performed.
Hepatocellular injury, as measured by serum levels of the
liver enzyme alanine aminotransferase (ALT), was sub-
stantially attenuated in PHD1!/! mice after I/R (serum
ALT: 2960 $ 543 IU/L in WT vs 1210 $ 351 IU/L in
PHD1!/!; n & 6; P & .02). The genotypic difference in
liver damage was specific for the I/R, as serum ALT levels
were similar in sham-operated mice (serum ALT: 271 $
30 IU/L in WT vs 238 $ 73 IU/L in PHD1!/!; n& 6; P&
not significant).
Histological evaluation of I/R-exposed WT livers re-
vealed extensive necrosis. Consistent with the oxygen-
gradient in ischemic liver,3 necrosis occurred mostly in
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Figure 1. Reduced hypoxic
hepatocyte damage in ischemic
PHD1!deficient (PHD1!/!) liv-
ers. (A) Hematoxylin and eosin
staining revealing normal ap-
pearance of healthy PHD1!/!
(right) and wild-type (WT) livers
(left). (B) Hematoxylin and eo-
sin-staining reveals hepatocyte
vacuolization (arrowheads) and
swelling (white arrows) in WT
(left), but not PHD1!/! livers
(right) in ischemic conditions.
Note preserved sinusoidal
spaces in PHD1!/! livers
(black arrows). (C!E) Quantifi-
cation of hepatocyte size (C),
sinusoidal diameter (D), and
erythrocyte velocity (E) reveal-
ing reduced ischemic hepato-
cyte swelling and preserved
sinusoidal lumen in ischemic
PHD1!/! livers. *P % .01,
**P % .001, n & 4. (F) Cellular
energy charge, revealing im-
proved preservation in ischemic
PHD1!/! livers. *P% .02, n& 4.
Bar graphs: mean $ standard
error of mean; scale bars in
(A,B) & 50 "m. PV, branch of
portal vein; NS, not significant.
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perivenular zones with sparing of periportal fields (Figure
2A). Decreased cytoplasmic staining, loss of nuclei, and
red cell congestion, all characteristic features of liver
necrosis, were attenuated in post-I/R livers of PHD1!/!
mice (Figure 2A). Morphometry revealed necrosis in up
to 60% of I/R-subjected liver lobes in WT mice, while only
30% of ischemic liver regions showed more subtle signs of
cellular dysfunction and demise in PHD1!/!mice (Figure
2B). TUNEL-staining also revealed more severe hepato-
cyte death in I/R-challenged WT than PHD1!/! livers
(Figure 2C). To confirm the protective effect of PHD1-
deficiency against liver I/R damage, we assessed survival
of mice subjected to hepatic I/R, followed by surgical
resection of all nonischemic liver lobes. Up to 57% of all
WT mice subjected to liver I/R and resection died within
48 hours of surgery, whereas 100% of PHD1!/! mice
undergoing the same procedure survived (Figure 2D).
Thus, loss of PHD1 increased the resistance of hepato-
cytes against lethal I/R damage.
Short-Term Silencing of PHD1 Protects
Against Hepatic I/R Damage In Vivo
We next determined whether short-term silencing
of PHD1 in vivo might suffice to protect mice against
hepatic I/R damage. This would allow us to address
whether permanent inactivation of PHD1 was required
to establish the protective state, or whether short-term
inhibition might already suffice—a question of medical
relevance when considering PHD1 inhibition as a possi-
ble therapeutic option. Because selective PHD1 inhibitors
are not available, we silenced PHD1 by using a construct
designed to produce a short hairpin interference RNA
against PHD1 (shPHD1KD). As control, we applied a con-
struct that differed by a mismatch of 10 nucleotides
(shPHD1CTR). For in vivo use, we cloned adenoviral vectors
AdshPHD1CTR and AdshPHD1KD, expressing these short
hairpin interference RNAs. The efficiency and specificity
of AdshPHD1KD to silence PHD1 were first tested in
AML12 hepatocytes (Supplementary Note 3). We took
advantage of the fact that intravenous injection of
adenoviral vectors nearly selectively transduces the ma-
jority of hepatocytes.19 Because pilot experiments re-
vealed that intravenous injection of AdshPHD1KD in WT
mice reduced hepatic expression of PHD1 only incom-
pletely (not shown), PHD1"/! mice were used, which
express reduced PHD1 levels (PHD1 messenger RNA lev-
els, percent of WT: 65% $ 8%; n & 10; P % .05). Intrave-
nous injection of AdshPHD1KD in PHD1"/! mice (nearly)
completely eliminated hepatic expression of PHD1, at
both messenger RNA and protein levels, while expression
of PHD2 or PHD3 was not altered; in contrast,
AdshPHD1CTR treatment did not affect hepatic PHD1
expression (Figure 3A and B).
Figure 2. Loss of PHD1 pro-
tects against hepatic I/R dam-
age. (A) Hematoxylin and eosin
(HE) staining revealing exten-
sive hepatocyte damage in
wild-type (WT) (left) but less in
PHD1-deficient (PHD1!/!) liv-
ers (right) after CV, central vein;
PV, portal vein. Scale bars &
100 "m. (B, C) Quantification
of necrotic areas (B) and
TUNEL-positive nuclei (C), re-
vealing decreased I/R-induced
hepatocyte death in PHD1!/!
livers. Bars represent mean $
standard error of mean *P %
.02, n & 5. (D) Survival curves,
revealing improved survival of
PHD1!/! mice after liver I/R
and resection of nonischemic
liver lobes. *P & .03, n & 6 by
log rank test.
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Knockdown of PHD1, performed 5 days prior to he-
patic ischemia (to allow sufficient adenoviral transgene
expression and turnover of preexisting PHD1 protein),
induced resistance of PHD1"/! livers against I/R damage.
Indeed, serum ALT levels were reduced in AdshPHD1KD-
treated PHD1"/! mice as compared to littermates in-
jected with AdshPHD1CTR (Figure 3C). Notably, liver I/R
damage in AdshPHD1CTR injected PHD1"/! and untreated
Figure 3. Short-term inhibition
of PHD1 protects against he-
patic I/R damage. (A) Immuno-
blot of liver lysates, revealing ef-
fective knock-down of PHD1
protein in PHD1"/!mice treated
with AdshPHD1KD, but not
AdshPHD1CTR. PHD1 protein
expression in livers from healthy
wild-type (WT) and PHD1!/!
mice was assessed as control.
Equal amounts of protein were
loaded. (B) Real-time reverse
transcription polymerase chain
reaction analysis revealing resid-
ual expression of PHD1, PHD2,
and PHD3 transcripts in livers
fromPHD1"/!mice treatedwith
AdshPHD1KD or AdshPHD1CTR.
*P % .0001, n & 7. (C) Attenu-
ated serum alanine aminotrans-
ferase levels in I/R-treated
PHD1"/! mice, following short-
term inhibition of PHD1 via
AdshPHD1KD. *P& .03, n& 10.
(D) Hematoxylin and eosin (HE)
staining, revealing extensive
I/R damage in AdshPHD1CTR–
treated- (left), but not in
AdshPHD1KD–treated animals
(right). PV, branch of portal vein.
Bars represent mean $ stan-
dard error ofmean.Scale bars in
(D)& 100 "m.
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WT mice was comparable (serum ALT: 2965 $ 543 IU/L
in untreated WT vs 3690 $ 982 IU/L in AdshPHD1CTR
treated PHD1"/!; n & 7; P & not significant). Consis-
tently, silencing of PHD1 attenuated I/R-induced hepa-
tocyte death (percent necrotic liver area: 53 $ 11 in
AdshPHD1CTR-treated PHD1"/! vs 15$ 5 in AdshPHD1KD-
treated PHD1"/!; n & 4; P & .027; Figure 3D). Thus,
short-term inhibition of PHD1 protects hepatocytes
against I/R.
Loss of PHD1 Reduces Oxidative Stress in
I/R-Treated Livers
After having established that permanent loss or
short-term silencing of PHD1 provided protection of
hepatocytes against I/R injury, we performed experi-
ments in an effort to start unraveling the underlying
mechanisms of this protection. We first investigated
whether the protection of PHD1!/! livers against I/R-
damage might be related to genotypic differences in the
production of toxic ROS, known to contribute to hepatic
I/R-damage.2 Therefore, livers were immunostained for
8-OHdG, a biomarker of oxidative stress.9 Livers of
healthy or sham-operated animals did not exhibit any
signs of 8-OHdG staining (not shown). In I/R-exposed
WT livers, a substantial fraction of hepatocyte nuclei
stained positively (Figure 4A). By contrast, many fewer
nuclei stained for 8-OHdG in I/R-exposed PHD1!/! liv-
ers (Figure 4A and B). As an alternative readout for
ROS-production in I/R-treated livers, we determined the
oxidation of the antioxidant glutathione to glutathione-
Figure 4. Oxidative stress
in reperfused PHD1!deficient
(PHD1!/!) livers. (A) 8-OHdG
staining, revealing substantial
oxidative damage in hepatic
I/R-exposed wild-type (left),
but only minimal in PHD1!/!
livers (right). CV, central vein.
Scale bars& 50 "m. (B) Histo-
morphometric quantification of
8-OHdG-stained hepatocyte
nuclei in I/R-challenged livers.
(C) Relative ratio of glutathione-
disulfide to total glutathione in
baseline and I/R-challenged
livers. Bars represent mean $
standard error of mean; *P %
.05, n & 5; **P % .01, n & 4.
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disulfide. The relative ratio of glutathione-disulfide to
total glutathione was markedly increased in WT livers
after I/R-exposure, indicating oxidative stress (Figure 4C).
In comparison, this ratio was significantly attenuated in
I/R-treated PHD1!/! livers (Figure 4C). Thus, PHD1-
deficiency attenuated oxidant stress after I/R. Additional
analysis revealed that only minor genotypic differences in
leukocyte infiltration occurred upon I/R challenge (Sup-
plementary Figure S3A and B).
Loss of PHD1 Lowers Oxygen Consumption
We then sought to delineate some of the initial
molecular mechanisms through which loss of PHD1 re-
duces oxidative stress in ischemic hepatocytes. We re-
cently demonstrated that loss of PHD1 protected against
skeletal muscle cell death induced by oxidative stress; this
protection relied on a decrease in oxygen consumption,
as respiration generates ROS in hypoxic conditions.20
Oxidative metabolism and oxygen consumption were re-
duced in PHD1!/! muscle, because PHD1 deficiency up-
regulated PDK1, which inhibits PDC and also, indirectly,
entry of glycolytic intermediates into the TCA cycle and
oxidative metabolism.9 To assess whether this mecha-
nism was also operational in PHD1!/! hepatocytes, we
determined the expression of PDK isoenzymes in the
liver. By real-time reverse transcription polymerase chain
reaction and immunoblotting, levels of PDK1 were in-
creased in PHD1!/! livers (PDK1 protein, percent of WT:
154% $ 16%; n & 6; P & .03, Figure 5A and B). Accord-
ingly, PDC activity was slightly but significantly attenu-
ated in livers from healthy PHD1!/! mice (Figure 5C).
The up-regulation of PDK1 in PHD1!/! livers was spe-
cific, as the expression of other PDKs was not altered
(Supplementary Note 8).
Figure 5. Decreased oxygen consumption in PHD1!deficient (PHD1!/!) livers. (A) Real-time reverse transcription polymerase chain reaction
revealing enhanced PDK1 expression in PHD1!/! livers. (B) Representative immunoblots, revealing enhanced expression of PDK1, but not PDK2-
or PDK3 protein in liver lysates from healthy PHD1!/! mice. Voltage-dependent anion channel (VDAC1!) was used to assure equal loading. (C)
Measurements of the activity of the PDC in healthy liver tissue. (D) Respirometry, revealing reduced oxygen consumption of PHD1!/! hepatocytes
supplied with glucose as a metabolic substrate. Triplicate measurements, 1 of 3 representative experiments is shown. (E) Pimonidazole staining,
revealing severe hypoxia in ischemic WT hepatocytes (left), and attenuated hypoxia in ischemic PHD1!/! hepatocytes (right). Bars represent mean
$ standard error of mean; *P % .05, n & 3. Scale bars in (E) & 50 "m. PV, branch of portal vein.
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To investigate whether PHD1!/! hepatocytes also con-
served oxygen, we used respirometry to measure oxygen
consumption of isolated hepatocytes when supplied with
glucose, as this is the key fuel during liver ischemia. In
these conditions, PHD1!/! hepatocytes consumed less
oxygen (Figure 5D). Also, silencing of PHD1 reduced
oxygen consumption of AML12 hepatocytes in the pres-
ence of glucose (Supplementary Note 9; Supplementary
Figure S4A). Consistently staining for the hypoxia
marker pimonidazole revealed that hepatocytes of both
genotypes had comparable intracellular oxygen levels in
baseline conditions (Supplementary Figure S4B), but af-
ter 90 minutes of ischemia, WT hepatocytes exhibited
more severe signs of intracellular hypoxia than PHD1!/!
hepatocytes (Figure 5E). Quantification revealed a 40% $
6% reduction of pimonidazole-stained areas in ischemic
PHD1!/! livers (n & 5; P % .01).
Initial studies of anaerobic glucose metabolism sug-
gested that increased glycolytic production of energy,
besides the reduced oxidative stress, might contribute to
the improved tolerance of PHD1!/! livers against is-
chemic and I/R injury (Supplementary Note 10; Supple-
mentary Figure S4C).
Role of Downstream HIFs in Hypoxia
Tolerance
We finally explored whether the hypoxia tolerance
was conferred by stabilization of hypoxia inducible fac-
tors (HIFs) in PHD1!/! livers. In baseline conditions,
HIF-2! protein levels were higher in PHD1!/! than WT
livers (Figure 6A). After onset of ischemia, HIF-2! levels
were up-regulated in both genotypes, indicating that they
perceived hypoxia; as in baseline conditions, HIF-2! lev-
els were higher in ischemic PHD1!/! than WT livers (not
shown). I/R-treatment also up-regulated HIF-2! levels in
both genotypes, but HIF-2! levels were again higher in
PHD1!/! livers (Figure 6A). Hepatic HIF-1! protein was
barely detectable in baseline conditions, and also up-
regulated by ischemia (not shown) and I/R-treatment
(Figure 6A). In general, loss of PHD1 up-regulated
HIF-2! levels more than HIF-1! levels (Figure 6A).
To assess the relevance of HIF-2! and HIF-1!, we
silenced their expression in hepatocytes isolated fromWT
or PHD1!/! mice. Transfection with interference RNA
resulted in incomplete silencing of HIF-1! or HIF-2!
messenger RNA levels by '50% (Supplementary Note
11). To test whether these reduced HIF levels were capa-
ble of reverting the hypoxia tolerance of PHD1!/! hepa-
tocytes, we used a model of simulated I/R in vitro.14 In
accordance with our in vivo findings, loss of PHD1 in-
creased the survival of hepatocytes exposed to simulated
I/R (Figure 6B). Partial silencing of HIFs did not affect
the viability of WT hepatocytes (Figure 6B). By contrast,
incomplete silencing of HIF-2! partially reverted the
hypoxia protection of PHD1!/! hepatocytes, while silenc-
ing of HIF-1! was ineffective (Figure 6B), suggesting that
HIF-2! may have a more prominent role in regulating
the hypoxia tolerance of PHD1!/! livers.
Discussion
Here, we used mice lacking PHD1, as well as
interference RNA!mediated hepatocyte-specific knock-
down of the PHD1 gene in vivo to demonstrate that
germline loss or short-term silencing of PHD1 provides
hypoxia tolerance to the liver. These results extend pre-
vious findings that PHD1-deficiency conveys hypoxia tol-
erance to metabolically active tissues such as skeletal
muscle,9 and underline the potential therapeutic value of
targeting PHD1 in order to prevent hypoxia-induced liver
damage.
Liver cells are highly dependent on oxygen and are
therefore vulnerable to hypoxia or I/R-injury.3 For exam-
ple, even a drop in cellular energy charge of %10% below
a critical vital threshold suffices to induce hepatocyte
death.17,18 The key finding of this study is that loss of
PHD1 confers improved protection against acute is-
chemia and I/R injury. Furthermore, this protective state
does not require permanent inactivation of PHD1, nei-
ther is its absence in all tissues required, but can be
induced by short-term silencing of PHD1 in the liver
alone. Not only were there clear morphological signs of
enhanced cellular protection (as evidenced by the reduced
hepatocyte swelling, vacuolization, and karyolysis) result-
ing in improved residual perfusion after releasing vascu-
lar occlusion (as evidenced by the flow measurements),
but PHD1!/! hepatocytes also exhibited reduced signs of
oxidative stress and were capable of maintaining their
cellular energy charge at higher levels.
Excessive oxidative stress inactivates key mitochondrial
and cellular enzymes and perturbs structural compo-
nents, overall leading to cellular demise. Loss of PHD1
provided hepatocytes a remarkable protection against
Figure 6. Role of HIF-2!. (A) Immunoblot of nuclear extracts, re-
vealing elevated protein levels of HIF-2! and, less extensively, also of
HIF-1! in PHD1!deficient (PHD1!/!) liver at baseline conditions,
and following I/R. Tubulin was used as a loading control. (B) Survival
of isolated hepatocytes exposed to simulated I/R in vitro revealing
that silencing of HIF-2!, but not HIF-1!, partly reverts the hypoxia
tolerance of PHD1!/! cells. Hepatocyte viability was determined by
WST-1 assay. Measurements were carried out 4 times; 1 of 3 rep-
resentative experiments is shown. Bars represent mean $ standard
error of mean; *P % .01, n & 4.
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oxidative stress, by lowering/preventing generation of
excessive amounts of ROS, as also occurs in PHD1!/!
skeletal muscle fibers.9 Similar to the latter,9 expression
of PDK1 was up-regulated with an accompanying reduc-
tion in PDC activity in PHD1!/! hepatocytes. Because
PDC acts as a gatekeeper to regulate the entry of glyco-
lytic intermediates in the Krebs cycle, a decrease (even
when incomplete) of its activity might be expected to
slow down oxidative metabolism and, hence, to conserve
oxygen.9 This metabolic adaptation is crucial for cells to
survive life-threatening episodes of hypoxia as it reduces/
prevents mitochondrial generation of excessive amounts
of ROS. Indeed, even though ROS are a natural byprod-
uct of mitochondrial respiration, they can be generated
in excess in hypoxic conditions.21,22 When ischemic cells
continue to consume oxygen in mitochondrial respira-
tion (as occurs in ischemic WT hepatocytes or myofibers;
see pimonidazole staining), production of ROS is in-
creased and reaches toxic levels, which cause irreversible
damage to mitochondrial respiratory enzymes.9 Thus,
similar to ischemic PHD1!/! skeletal muscle cells,9 the
reduced oxygen consumption in PHD1!/! hepatocytes
prevents excessive formation of toxic ROS and is, thereby,
likely a predominant mechanism whereby loss of PHD1
provides hepatocytes hypoxia tolerance and protection
against I/R injury.
While reperfusion is well known to initiate a cascade of
deleterious events,2 part of the protection of PHD1!/!
hepatocytes against I/R injury may result from cellular
changes during the ischemic challenge, ie, prior to reper-
fusion. Indeed, already during the ischemic stress,
PHD1!/! hepatocytes were less hypoxic (pimonidazole
staining), indicating that they conserved oxygen despite
the reduced oxygen supply, in contrast to their WT coun-
terparts, which continued to consume oxygen. Further-
more, measurements of the cellular energy charge re-
vealed that PHD1!/! hepatocytes experienced an acute
drop on vascular occlusion, but then seemed to better
preserve their energy charge levels above critical thresh-
olds. Probably as a consequence, PHD1!/! hepatocytes
exhibited reduced signs of swelling at the end of the
ischemic period, thereby improving flow upon reopening
of the vascular clamps and attenuating microcirculatory
perfusion failure, which is a well-known major determi-
nant of liver dysfunction following hepatic I/R.23 All this
evidence indicates that loss of PHD1 already induced
critical changes during ischemia, which prepared hepa-
tocytes better to survive the subsequent reperfusion in-
jury. However, given that hepatocyte oxidative stress was
strikingly attenuated after 8 hours of reperfusion, when
mitochondria represent a major source of ROS-produc-
tion in I/R,2 it is conceivable that cellular adaptations
provoked by loss of PHD1 likewise affected hepatocyte
survival during the reperfusion phase as well.
An interesting question is whether HIF-1! or HIF-2!
are downstreammediators of PHD1 in providing hypoxia
tolerance to hepatocytes. As expected, HIF levels in WT
hepatocytes were elevated after onset of ischemia due to
shortage of oxygen (not shown) and even more so after
onset of I/R, likely because abundant generation of ROS
inhibits PHD activity. In baseline ischemic and post-I/R
conditions, HIF-1! but especially HIF-2! levels were
more abundant in PHD1!/! livers. This genotypic differ-
ence in HIF levels cells is caused, in part, by the absence
of PHD1, which elevates HIF levels even when the re-
duced oxygen consumption in these mice counteracts
this up-regulation (through redistribution of oxygen into
the cytosol); similar findings were obtained previously in
PHD-knockout mice.9,24 In post-I/R conditions, PHD1!/!
hepatocytes suffer less oxidative stress but are better
perfused and more viable and therefore more competent
to up-regulate HIFs, and are also capable of maintaining
better cellular respiration, which leads to a redistribution
of oxygen away from the cytosol, and a further up-
regulation of HIF levels.
Functional evidence for the importance of HIF-2! was
provided by findings that the hypoxia tolerance of hepa-
tocytes was at least partly reverted by silencing HIF-2!
expression in vitro, whereas this was not the case for
HIF-1!. PDK1 is a direct target for HIF-1!,21,22 but he-
patic regulation of PDK1 by HIF-2! should not be ex-
cluded because recent reports assigned HIF-2! a predom-
inant role in hepatic regulation of archetypical HIF-1!
target genes, such as Bnip3.25,26 Although a possible role
of HIF-1! should not be discarded prematurely (perhaps
at deeper levels of hypoxia), these findings suggest that
HIF-2! is involved in the hypoxia tolerance pathway not
only in the skeletal muscle,9 but also in the liver.
Our previous studies in the PHD1!/! muscle indicate
that compensatory glycolytic generation of energy con-
tributed to the hypoxia tolerance of myofibers and their
protection against ischemia.9 This seems to be also the
case in ischemic PHD1!/! hepatocytes. Indeed, in
PHD1!/! liver, glycogen stores were increased in baseline
conditions, while glycogen breakdown rates were higher
in ischemic conditions, probably due to an increased
utilization of glycogen for glycolytic generation of en-
ergy. Of note, high glycogen reserves promote hepatocyte
survival in rodent models of hepatic ischemia,21 as well as
in clinical settings.27 Thus, besides the reduced oxidative
damage, an increased anaerobic glucose catabolism may
have allowed PHD1!/! hepatocytes to survive better the
ischemic and I/R injury.
This study highlights possible medical relevance of
specific PHD1-inhibition to treat medical conditions
caused by severe acute hypoxia. We show here, for the
first time, that short-term inhibition of PHD1 reduces
hypoxic liver damage in vivo. This finding is of clinical
relevance, as the increased incidence of liver transplanta-
tion for patients with end-stage liver disease demands
novel therapeutic strategies to protect donor organs from
hypoxic damage.1,28 Moreover, our data may also suggest
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that therapeutic PHD1-targeting might be applicable to
improve residual liver function in subjects undergoing
liver ischemia and resection, as occurs in resection of liver
metastases. The therapeutic potential of pharmacologic
HIF stabilization to alleviate acute hypoxic tissue damage
has been highlighted in rodents.29–31 However, different
from nonspecific inhibition of all PHDs, we observed
hypoxia tolerance in mice lacking PHD1 selectively, but
expressing normal levels of PHD2 and PHD3, highlight-
ing that hepatic protection against hypoxia is a specific
effect of PHD1-inhibition. Thus, further investigation
may be warranted to design clinical strategies that spe-
cifically target PHD1 to protect the liver against severe
hypoxia in conditions of transplantation, surgical liver
resection, veno-occlusive disease, hemorrhagic shock re-
suscitation or perhaps even heart failure.
Supplementary Material
Note: To access the supplementary material
accompanying this article, visit the online version of
Gastroenterology at www.gastrojournal.org, and at doi:
10.1053/j.gastro.2009.09.057.
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